RESUMEN
ABSTRACT: Maturation of fibrillar collagen is known to play a crucial role in the pathophysiology of myocardial fibrosis. Procollagen C-proteinase enhancer 1 (PCPE1) has a key role in procollagen maturation and collagen fibril formation. The phenotype of both male and female PCPE1 knock-out mice was investigated under basal conditions to explore the potential of PCPE1 as a therapeutic target in heart failure. Global constitutive PCPE1-/- mice were generated. Serum procollagen I C-terminal propeptide, organ histology, and cutaneous wound healing were assessed in both wild type (WT) and PCPE1-/- mice. In addition, the cardiac expression of genes involved in collagen metabolism was investigated and the total and insoluble cardiac collagen contents determined. Cardiac function was evaluated by echocardiography. No differences in survival, clinical chemistry, or organ histology were observed in PCPE1-/- mice compared with WT. Serum procollagen I C-terminal propeptide was lower in PCPE1-/- mice. Cardiac mRNA expression of Bmp1, Col1a1, Col3a1, and Loxl2 was similar, whereas Tgfb and Loxl1 mRNA levels were decreased in PCPE1-/- mice compared with sex-matched WT. No modification of total or insoluble cardiac collagen content was observed between the 2 strains. Ejection fraction was slightly decreased in PCPE1-/- male mice, but not in females. Finally, wound healing was not altered in PCPE1-/- mice. PCPE1 deficiency does not trigger any major liabilities and does not affect cardiac collagen content nor its function under basal conditions. Further studies are required to evaluate its role under stressed conditions and determine its suitability as a therapeutic target for heart failure.
Asunto(s)
Colágeno/metabolismo , Proteínas de la Matriz Extracelular/deficiencia , Miocardio/metabolismo , Aminoácido Oxidorreductasas/genética , Aminoácido Oxidorreductasas/metabolismo , Animales , Proteína Morfogenética Ósea 1/genética , Proteína Morfogenética Ósea 1/metabolismo , Colágeno/genética , Cadena alfa 1 del Colágeno Tipo I/genética , Cadena alfa 1 del Colágeno Tipo I/metabolismo , Colágeno Tipo III/genética , Colágeno Tipo III/metabolismo , Proteínas de la Matriz Extracelular/genética , Femenino , Regulación de la Expresión Génica , Genotipo , Masculino , Ratones Endogámicos C57BL , Ratones Noqueados , Fragmentos de Péptidos/sangre , Fenotipo , Procolágeno/sangre , Volumen Sistólico , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta/metabolismo , Función Ventricular Izquierda , Cicatrización de HeridasRESUMEN
Dexamphetamine (AMPH) is a psychostimulant drug that is used both recreationally and as medication for attention deficit hyperactivity disorder. Preclinical studies have demonstrated that repeated exposure to AMPH can induce damage to nerve terminals of dopamine (DA) neurons. We here assessed the underlying neurobiological changes in the DA system following repeated AMPH exposure and pre-treated rats with AMPH or saline (4 times 5 mg/kg s.c., 2 hours apart), followed by a 1-week washout period. We then used pharmacological MRI (phMRI) with a methylphenidate (MPH) challenge, as a sensitive and non-invasive in-vivo measure of DAergic function. We subsequently validated the DA-ergic changes post-mortem, using a.o. high-performance liquid chromatography (HPLC) and autoradiography. In the AMPH pre-treated group, we observed a significantly larger BOLD response to the MPH challenge, particularly in DA-ergic brain areas and their downstream projections. Subsequent autoradiography studies showed that AMPH pre-treatment significantly reduced DA transporter (DAT) density in the caudate-putamen (CPu) and nucleus accumbens, whereas HPLC analysis revealed increases in the DA metabolite homovanillic acid in the CPu. Our results suggest that AMPH pre-treatment alters DAergic responsivity, a change that can be detected with phMRI in rats. These phMRI changes likely reflect increased DA release together with reduced DAT binding. The ability to assess subtle synaptic changes using phMRI is promising for both preclinical studies of drug discovery, and for clinical studies where phMRI can be a useful tool to non-invasively investigate DA abnormalities, e.g. in neuropsychiatric disorders.
Asunto(s)
Encéfalo/efectos de los fármacos , Estimulantes del Sistema Nervioso Central/farmacología , Dextroanfetamina/farmacología , Dopamina/metabolismo , Metilfenidato/farmacología , Animales , Encéfalo/metabolismo , Estimulantes del Sistema Nervioso Central/efectos adversos , Cromatografía Líquida de Alta Presión , Cuerpo Estriado/metabolismo , Dextroanfetamina/efectos adversos , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Inhibidores de Captación de Dopamina/farmacología , Neuronas Dopaminérgicas/efectos de los fármacos , Esquema de Medicación , Proteína Ácida Fibrilar de la Glía/metabolismo , Hemodinámica , Inmunohistoquímica , Imagen por Resonancia Magnética , Masculino , Ratas , Ratas Sprague-Dawley , Receptores de Dopamina D2/metabolismoRESUMEN
Goal-directed behaviors are thought to be supported by a neural circuit encompassing the prefrontal cortex, the dorsomedial striatum, the amygdala, and, as more recently suggested, the limbic thalamus. Since evidence indicates that the various thalamic nuclei contribute to dissociable functions, we directly compared the functional contribution of the mediodorsal thalamus (MD) and of the anterior thalamic nuclei (ATN) in a new task assessing spatial goal-directed behavior in a cross-maze. Rats sustaining lesions of the mediodorsal or the anterior thalamus were trained to associate each of the two goal arms with a distinctive food reward. Unlike control rats, both lesioned groups failed to express a bias for the goal arm corresponding to the non-devalued outcome following devaluation by sensory-specific satiety. In addition, MD rats were slower than the other groups to complete the trials. When tested for spatial working memory using a standard non-matching-to-place procedure in the same apparatus, ATN rats were severely impaired but MD rats performed as well as controls, even when spatial or temporal challenges were introduced. Finally, all groups displayed comparable breaking points in a progressive ratio test, indicating that the slower choice performance of MD rats did not result from motivational factors. Thus, a spatial task requiring the integration of instrumental and Pavlovian contingencies reveals a fundamental deficit of MD rats in adapting their choice according to goal value. By contrast, the deficit associated with anterior thalamic lesions appears to simply reflect the inability to process spatial information.
Asunto(s)
Núcleos Talámicos Anteriores/fisiología , Conducta de Elección , Objetivos , Aprendizaje por Laberinto/fisiología , Núcleo Talámico Mediodorsal/fisiología , Animales , Conducta de Elección/fisiología , Condicionamiento Operante/fisiología , Masculino , Memoria a Corto Plazo/fisiología , Ratas , Ratas Long-Evans , Recompensa , Percepción Espacial/fisiologíaRESUMEN
The limbic thalamus is a heterogeneous structure with distinctive cortical connectivity. A recent review suggests that the mediodorsal thalamic nucleus (MD), unlike the anterior thalamic nuclei (ATN), may be involved in selecting relevant information in tasks relying on executive functions. We compared the effects of excitotoxic lesions of the MD or the ATN on the acquisition of a simple conditional discrimination in rats. When required to choose from two levers according to auditory or visual cues, ATN rats and sham-lesioned rats performed to the same levels and displayed similar acquisition curves. Under the same conditions, MD rats' acquisition of the task was markedly delayed. This group nevertheless attained nearly normal performances after more extensive training. Furthermore, all rats learned reversal of the original discrimination at the same rate. These results highlight functional specialization within the limbic thalamus and support the notion that MD contributes to the identification of relevant dimensions in conditional tasks during the initial stages of acquisition.